pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$FOLDAMICUS THERAPEUTICS, INC.

$FOLD14.490.00%
Princeton, NJ, USupdated 21d ago

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
4
marketed
3
phase 3
1
catalysts ytd
3
approvals ytd
0
recalls ytd
0

Pipeline(4)

pipeline depth4 products
Phase 3: 1Marketed: 3
1Phase 33Marketed
Marketed
cipaglucosidase alfa
Pompe Disease
Marketed
cipaglucosidase alfa + miglustat
Pompe Disease
Marketed
migalastat hydrochloride
Fabry Disease
Phase 3
propagermanium
Focal Segmental Glomerulosclerosis (FSGS)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variantsrecruitingn=8
  • phase3A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Diseaseactive not recruitingn=14
  • —A Study of Patients With Fabry Disease (US Specific)recruitingn=450
  • —A Global Prospective Observational Registry of Patients With Pompe Diseaserecruitingn=500
  • phase3A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)completedn=119
  • phase3Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Diseasecompletedn=16
  • —A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.completedn=82
  • phase3A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18recruitingn=36
more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Mar 2, 26SELLCampbell Bradley L· President and CEO22,500 sh @ $14.35−$323K↗
🐶 Hiring Signal
No open roles indexed yet — view AMICUS THERAPEUTICS, INC. jobs →

News

  • 7 biopharma M&A deals where layoffs followed
    Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired b…
    biospace · 22h ago
  • Kolon TissueGene cuts 37 US staffers after Phase 3 fail
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 1d ago
  • Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
    Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.
    biospace · 2d ago
  • AI clinical monitoring agent can deliver up to 82 times the ROI in oncology: report
    A new analysis from the Tufts Center for the Study of Drug Development (CSDD) found that an AI clinical monitoring agent can deliver an estimated 82-fold return on investment in phase 3 oncology tr…
    fiercebiotech · 8d ago
  • After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
    With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.
    fiercebiotech · 9d ago
  • The China Debate: Biotech deserves a deeper discussion
    For the last few months, I've been watching the debate about the US-China biotech rivalry unfold, and I've been unsatisfied. There are great, smart people arguing about the future of the biotech in…
    endpoints · 16d ago
  • ‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
    Biogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.
    fiercebiotech · 22d ago
  • FDA approves Freenome colorectal cancer blood test to be marketed by Abbott
    The FDA has approved Freenome’s new blood-based colorectal cancer test, SimpleScreen CRC, which Abbott will exclusively market in the U.S.
    fiercebiotech · 24d ago
  • Opinion: STAT readers on the value of primary care, obesity as a disease, and more
    “The real opportunity is to move beyond policies and narratives that pit specialties against one another,” presidents of the AAFP, ACP, and AAP write.
    stat · 1mo ago
  • India’s life sciences sector at turning point for innovation: Report
    Structural gaps in areas including clinical execution and funding limit India’s ability to scale up innovation, according to a report from Boston Consulting Group and HealthKois.
    biospace · 1mo ago
view all news mentions →
identifiers
ticker
$FOLD
SEC CIK
0001178879
country
US
source
sec_tickers
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 13m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?